Screener / SEC EDGAR /CIK 0000313143 /10-K filed May 20, 2026, compared with May 21, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Haemonetics Corp HAE

Compare with peers Embed
CEO pay, fiscal year to Mar 28, 2026

Christopher A. Simon was paid $12.0M as reported, $8.1M at the share price

Proxy (DEF 14A)
CEO pay, as reported $12.0M salary, bonus and awards at grant value
CEO pay, actually paid $8.1M awards valued at the share price
$100 in the shares became $48 peer group: $65
CEO pay, 5 years $53.7M up 38% while net income fell 100%

Did pay move with results?

Each line is 100 in 2022 · pay versus performance table, proxy (DEF 14A)

075150225 20222023202420252026 Net income, 2022: 100Net income, 2023: 266Net income, 2024: 271Net income, 2025: 0Net income, 2026: 0 Net income 0 $100 invested, 2022: 100$100 invested, 2023: 130$100 invested, 2024: 134$100 invested, 2025: 99$100 invested, 2026: 76 $100 invested 76

When the pay line climbs faster than net income and the $100 line, pay rose more than results did; when it falls with them, it followed them. "Actually paid" re-values stock awards at the share price, so it moves with the stock. Numbers as the company tagged them in its proxy.

Pay against results, year by year

Pay versus performance · proxy, filed Jun 9, 2026

Fiscal year toCEOCEO pay (reported) CEO pay (actually paid) $100 became
Mar 28, 2026Christopher A. Simon $12.0M$8.1M $48
Mar 29, 2025Christopher A. Simon $10.7M$1.3M $63
Mar 30, 2024Christopher A. Simon $11.5M$10.2M $85
Apr 1, 2023Christopher A. Simon $10.7M$18.1M $82
Apr 2, 2022Christopher A. Simon $8.7M-$2.4M $63

Pay versus performance table of the proxy statement (DEF 14A) filed Jun 9, 2026, as tagged by the company in XBRL. Open the proxy

Pay against free cash flow per share, at peers

Change over the years each proxy covers · pay versus performance table, DEF 14A, and 10-K XBRL

CEO pay, as reported Free cash flow per share » runs past the edge. Pay is salary, bonus and awards at grant value. FCF per share is cash from operations less capital spending, over diluted shares, from the 10-K of the same fiscal year.

HAE: CEO pay rose 38% from FY2022 to FY2026 ($8.7M to $12.0M), while free cash flow per share rose 273% ($1.48 to $5.50). Open the proxy

Sources

The pay versus performance table of the latest proxy statement, as the company tagged it in XBRL.

Also

Cash & buybacks: what the company did with its cash in the same years.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/HAE/export.csv") into a cell.

Next:Crypto holdings
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.